Cetuximab, Cisplatin and BYL719 for HPV-Associated Oropharyngeal Squamous Cell Carcinoma

PHASE1/PHASE2WithdrawnINTERVENTIONAL

Timeline

Start Date

August 31, 2016

Primary Completion Date

August 31, 2019

Study Completion Date

August 31, 2024

Conditions

Carcinoma, SquamousSquamous Cell CarcinomaOropharyngeal NeoplasmsOropharyngeal Cancer

Interventions

DRUG

cisplatin

75 mg/m2 IV day 1 of each cycle

DRUG

Cetuximab

XXXX day 1, 8, and 15 of each cycle

DRUG

BYL719

200, 250, 300, or 350 mg/day by mouth every day